We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current AMBS market cap is 6.83k. The company's latest EPS is USD -0.0698 and P/E is 0.00.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 20M | 75k | 0 | 95k |
| Operating Income | -2.84M | 18.33M | -627k | -148k | -268k |
| Net Income | -10.38M | 18.38M | -627k | -10.2M | -4.76M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.48M | 24.79M | 24.87M | 14.71M | 10.21M |
| Total Liabilities | 31.22M | 33.74M | 34.36M | 34.63M | 34.87M |
| Total Equity | -27.74M | -8.96M | -9.48M | -19.93M | -24.67M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -6.9M | 1.02M | -83k | -9.93M | -4.5M |
| Investing | 6.07M | -2.03M | -81k | 9.97M | 4.5M |
| Financing | 781k | 1.01M | 163k | -45k | N/A |
| Market Cap | 6.83k |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 68.27M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -90.91% |
| 52 Week High | 0.0401 |
| 52 Week Low | 0.000001 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Amarantus Bioscience Holdings Inc (CE) |
| Address |
701 s carson street carson city, nevada 89701 |
| Website | https://www.amarantus.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
